Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKDCT225 in Claudin18.2-positive Advanced Solid Tumors
NCT06782425Phase 1Recruiting
- Sponsor
- Shenzhen Celconta Life Science Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XKDCT225 in solid tumor, gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA) and 1 more, sponsored by Shenzhen Celconta Life Science Co., Ltd. Primary endpoints: Dose limiting toxicity at 28 days, Maximum tolerated dose at 28 days and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
XKDCT225
03
Conditions
solid tumorgastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT06782425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782425.